^
Association details:
| Biomarker: | HER-2 expression |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Tukysa (tucatinib) (HER2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Preclinical Activity of HER2-Selective Tyrosine Kinase Inhibitor Tucatinib as a Single Agent or in Combination with Trastuzumab or Docetaxel in Solid Tumor Models
Published date:
04/02/2020
Excerpt:
In vivo, tucatinib is active in multiple HER2+ tumor models as a single agent and shows enhanced antitumor activity in combination with trastuzumab or docetaxel, resulting in improved rates of partial and complete tumor regression....Tucatinib monotherapy or in combination with trastuzumab significantly reduces tumor volume in HER2+ breast, gastric, colorectal, and esophageal PDX xenograft models.
DOI:
10.1158/1535-7163.MCT-19-0873
